Covered recipient · General Payments record
CESAR A PARRA
Allopathic & Osteopathic Physicians Pediatrics
General Payments · PY2018–2024
$1,190.40
- Reported across 59 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $300.69 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $81.28 | 4 |
| GlaxoSmithKline, LLC. | $49.29 | 3 |
| Phadia US Inc. | $47.29 | 2 |
| Merck Sharp & Dohme Corporation | $36.52 | 2 |
| BioMarin Pharmaceutical Inc. | $34.59 | 1 |
| Cranial Technologies, Inc | $31.48 | 2 |
| ACADIA Pharmaceuticals Inc | $20.24 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $20.24 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147986580 | CMS |
| BioMarin Pharmaceutical Inc. | $34.59 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127062086 | CMS |
| Cranial Technologies, Inc | $15.73 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082236428 | CMS |
| Cranial Technologies, Inc | $15.75 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082236430 | CMS |
| GlaxoSmithKline, LLC. | $16.24 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116693465 | CMS |
| GlaxoSmithKline, LLC. | $16.81 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116338939 | CMS |
| GlaxoSmithKline, LLC. | $16.24 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116662603 | CMS |
| Merck Sharp & Dohme LLC | $21.82 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141934937 | CMS |
| Merck Sharp & Dohme LLC | $14.70 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141724964 | CMS |
| PFIZER INC. | $24.40 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132030535 | CMS |
| PFIZER INC. | $19.21 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131710859 | CMS |
| PFIZER INC. | $17.13 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131896182 | CMS |
| PFIZER INC. | $20.54 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131222619 | CMS |
| Phadia US Inc. | $23.52 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067576866 | CMS |
| Phadia US Inc. | $23.77 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067576868 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.